NCT03176173Completed
Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy
Source: ClinicalTrials.gov · Last updated 5 Nov 2025
Brief summary (registry, in English)
This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with non-small cell lung cancer may help to improve response to immunotherapy anti-cancer treatment.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 45 (actual)
- First submitted
- 1 Jun 2017
- Start date
- 28 Jun 2017
- Primary completion date
- 24 Nov 2021
- Lead sponsor
- Stanford University
- Diseases
- Lung cancer
- NCT number
- NCT03176173
What you commit to
- Study type: Interventional
- Participants enrolled: 45
- From 28 Jun 2017 to the primary completion date, 24 Nov 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Untreated brain metastases, if not planned to be treated in this course of radiation therapy
Other
- Pregnancy or women of childbearing potential not willing/able to use contraception during protocol treatment
Who the study is looking for
- Has stage IV non-small cell lung cancer, or initially stage I-III disease with distant metastatic recurrence
- Age ≥ 18
- Has been receiving anti-PD-1 or anti-PD-L1 immunotherapy for at least four weeks (refer to section 4.2.1)
- Has had restaging imaging after initiation of immunotherapy, at least 4 weeks after pre-immunotherapy baseline imaging. CT or PET/CT of at least chest/upper abdomen must be performed within 4 weeks prior to registration. For patients with history of brain metastases, brain MRI or CT is required within 4 weeks of registration; for other patients brain MRI or CT is required within 12 weeks of registration. Diagnostic PET/CT performed as part of radiation simulation can be used as the restaging imaging.
- Most recent imaging shows measurable disease as defined by RECIST 1.1
- Evaluation by a Stanford medical oncologist must show:
- The patient is expected to continue on immunotherapy for at least three more months
- Imaging must show response, stable disease, or modest progression
- If there is modest progression, the patient must be clinically stable in terms of performance status and overall disease-related symptoms
- Has at least one extracranial tumor safely treatable with radical-dose radiation therapy and that has not been previously treated with radiation
- ECOG performance status 0-2
- Has the ability to understand and the willingness to sign a written informed consent document.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Stanford University, School of Medicine Coordinator of this site? Confirm its status | Palo Alto | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.